Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Nucl Med
Главные авторы: Pryma, Daniel A., Chin, Bennett B., Noto, Richard B., Dillon, Joseph S., Perkins, Stephanie, Solnes, Lilja, Kostakoglu, Lale, Serafini, Aldo N., Pampaloni, Miguel H., Jensen, Jessica, Armor, Thomas, Lin, Tess, White, Theresa, Stambler, Nancy, Apfel, Stuart, DiPippo, Vincent A., Mahmood, Syed, Wong, Vivien, Jimenez, Camilo
Формат: Artigo
Язык:Inglês
Опубликовано: Society of Nuclear Medicine 2019
Предметы:
Theranostics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://ncbi.nlm.nih.gov/pubmed/30291194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.217463
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы